Moreover, we definitively demonstrated that AKT activator (SC79) or JNK inhibitor (SP600125) could reverse the anticancer effects of rhoifolin on pancreatic cancer cells, including enhancement of antioxidant capacity, inhibition of proliferation, migration and invasion, and induction of apoptosis. Here, AKT1 is linked to familial pancreatic carcinoma.